Janssen deal and $16m financing pave development path for Vascular's nephropathy candidate
This article was originally published in Scrip
Executive Summary
Vascular Pharmaceuticals has closed a development agreement with Janssen Biotech concurrent with the completion of a $16 million Series A equity financing round for its preclinical candidate VPI-2690B to treat diabetic nephropathy.